|
[1] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40 (12) :1461-1465.
|
|
[2] VICTOR RG, HALEY RW, WILLETT DL, et al, Dallas Heart Study Investigators. The Dallas Heart Study:A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health[J]. Am J Cardiol, 2004, 93 (12) :1473-1480.
|
|
[3] SPELIOTES EK. Thwart your destiny; effect of nonacoholic fatty liver disease genes on steatosis, liver injury and cirrhosis varies by body mass index[J]. Hepatology, 2018, 68 (1) :372-374.
|
|
[4] YKI-JRVINEN H, LUUKKONEN PK. Heterogeneity of non-alcoholic fatty liver disease[J]. Liver Int, 2015, 35 (12) :2498-2500.
|
|
[5] SKOIEN R, RICHARDSON MM, JONSSON JR, et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways[J]. Liver Int, 2013, 33 (4) :624-632.
|
|
[6] LIU F, ZHAO JM, RAO HY, et al. Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease[J]. Am J Clin Pathol, 2017, 148 (6) :502-512.
|
|
[7] YOUNOSSI Z, HENRY L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality[J]. Gastroenterology, 2016, 150:1778-1785.
|
|
[8] KOEHLER EM, PLOMPEN EP, SCHOUTEN JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population:The Rotterdam study[J]. Hepatology, 2016, 63 (1) :138-147.
|
|
[9] KWOK R, CHOI KC, WONG GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J].Gut, 2016, 65 (8) :1359-1368.
|
|
[10] SOOKOIAN S, PIROLA CJ. Systematic review with meta-analysis:The significance of histological disease severity in lean patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2018, 47 (1) :16-25.
|
|
[11] KUMAR R, MOHAN S. Non-alcoholic fatty liver disease in lean subjects:Characteristics and implications[J]. J Clin Transl Hepatol, 2017, 5 (3) :216-223.
|
|
[12] European Association for the Study of the Liver (EASL) ; European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO) . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64 (6) :1388-1402.
|
|
[13] VAJRO P, LENTA S, SOCHA P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents:Position paper of the ESPGHAN Hepatology Committee[J]. J Pediatr Gastroenterol Nutr, 2012, 54 (5) :700-713.
|
|
[14] VOS MB, ABRAMS SH, BARLOW SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children:Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) [J]. J Pediatr Gastroenterol Nutr, 2017, 64 (2) :319-334.
|
|
[15] JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2018.[Epub ahead of print]
|
|
[16] WILDMAN-TOBRINER B, MIDDLETON MM, MOYLAN CA, et al.Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155 (5) :1428-1435.
|
|
[17] HSU C, CAUSSY C, IMAJO K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease:A systematic review and pooled analysis of individual participants[J]. Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[18] ROMERO-GMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67 (4) :829-846.
|
|
[19] KONERMAN MA, JONES JC, HARRISON SA. Pharmacotherapy for NASH:Current and emerging[J]. J Hepatol, 2018, 68 (2) :362-375.
|
DownLoad: